User profiles for "author:D. Wendling"

WENDLING D

Besançon
Verified email at chu-besancon.fr
Cited by 23648

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

…, E Stanislawska-Biernat, D Wendling… - Annals of the …, 2011 - ard.bmj.com
This first update of the ASAS/EULAR recommendations on the management of ankylosing
spondylitis (AS) is based on the original paper, a systematic review of existing …

The contribution of adipose tissue and adipokines to inflammation in joint diseases

E Toussirot, G Streit, D Wendling - Current medicinal chemistry, 2007 - ingentaconnect.com
Adipokines are proteins produced by white adipose tissue, which is an active secretory
organ. Regulation of immune and inflammatory responses is among the multiple …

Physical activity in patients with rheumatoid arthritis

…, N Tordi, C Prati, C Demougeot, F Mougin, D Wendling - Joint bone spine, 2016 - Elsevier
Introduction Rheumatoid arthritis (RA) is the most common chronic inflammatory joint
disease and is associated with an excess risk of cardiovascular disease. For the general …

ASAS/EULAR recommendations for the management of ankylosing spondylitis

…, RD Sturrock, S van der Linden, D Wendling… - Annals of the …, 2006 - ard.bmj.com
Objective: To develop evidence based recommendations for the management of ankylosing
spondylitis (AS) as a combined effort of the 'ASsessment in AS'international working group …

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

…, B Moura, P Remy, T Thomas, D Wendling… - Annals of the …, 2005 - ard.bmj.com
Objective: To assess the tolerance and efficacy of rituximab in patients with various
autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology …

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

…, C Michelet, J Morel, X Puéchal, D Wendling… - Annals of the …, 2011 - ard.bmj.com
Background Anti-tumour necrosis factor (TNF) therapy may be associated with opportunistic
infections (OIs). Objective To describe the spectrum of non-tuberculosis OIs associated with …

The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients

…, A Saraux, JM Treluyer, D van Der Heijde, D Wendling - Joint bone spine, 2011 - Elsevier
OBJECTIVES: The French Society of Rheumatology has initiated a large national
multicenter, longitudinal, prospective follow-up of patients presenting with early inflammatory …

Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.

D Wendling, E Racadot, J Wijdenes - The Journal of rheumatology, 1993 - europepmc.org
Interleukin 6 (IL-6) appears to be a potential mediator of inflammation that may contribute to
the pathogenesis of joint inflammation in RA. Anti-IL-6 monoclonal antibodies (Mab) may …

Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial

…, D Mulleman, C Lukas, D Wendling… - Annals of the …, 2015 - ard.bmj.com
Aim To test the efficiency of tumour necrosis factor blockers (adalimumab) in patients with
painful refractory (non-responders to analgesics and non-steroidal anti-inflammatory drugs …

Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial

…, E Dernis, C Richez, ME Truchetet, D Wendling… - Jama, 2022 - jamanetwork.com
Importance Few treatments are available for patients with glucocorticoid-dependent
polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in patients with active …